Maternal obesity and metabolic disorders associate with congenital heart defects in the offspring: a systematic review

Gitte Hedermann*[1], Paula L Hedley[1], Ida N Thagaard[1,2], Lone Krebs[3,4], Charlotte Kvist Ekelund[4,5], Thorkild IA Sørensen[6,7], Michael Christiansen[1,8]

[1] Department for Congenital Disorders, Danish National Biobank and Biomarkers, Statens Serum Institut, Copenhagen, Denmark

[2] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Slagelse Hospital, Slagelse, Denmark

[3] Department of Obstetrics and Gynaecology, Copenhagen University Hospital, Amager and Hvidovre Hospital, Copenhagen, Denmark

[4] Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

[5] Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

[6] Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark

[7] The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[8] Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

* Corresponding author. E-mail: gihc@ssi.dk (GH)

Abstract

Background

Congenital heart defects (CHDs) are the most common congenital malformations. The aetiology of CHDs is complex. Large cohort studies and systematic reviews and meta-analyses based on these have reported an association between higher risk of CHDs in the offspring and individual maternal metabolic disorders such as obesity, diabetes, hypertension, and preeclampsia, all conditions that can be related to insulin resistance or hyperglycaemia. However, the clinical reality is that these conditions often occur simultaneously. The aim of this review is, in consequence, both to evaluate the existing evidence on the association between maternal metabolic disorders, defined as obesity, diabetes, hypertension, preeclampsia, dyslipidaemia and CHDs in the offspring, as well as the significance of combinations, such as metabolic syndrome, as risk factors.

Methods

A systematic literature search of papers published between January 1, 1990 and October 6, 2019 was conducted using PubMed and Embase. Studies were eligible if they were published in English and were case-control or cohort studies. The exposures of interest were maternal overweight or obesity, hypertension, preeclampsia, diabetes, dyslipidaemia, and/or metabolic syndrome, and the outcome of interest was CHDs in the offspring. Furthermore, the studies were included according to a quality assessment score.

Results

Of the 2,076 identified studies, 30 qualified for inclusion. All but one study investigated only the individual metabolic disorders. Some disorders (obesity, gestational diabetes, and hypertension) increased risk of CHDs marginally whereas pre-gestational diabetes and early-onset preeclampsia were strongly associated with CHDs, without consistent differences between CHD subtypes. A single study suggested a possible additive effect of maternal obesity and gestational diabetes.

Conclusions

Future studies of the role of aberrations of the glucose-insulin homeostasis in the common aetiology and mechanisms of metabolic disorders, present during pregnancy, and their association, both as single conditions and – particularly – in combination, with CHDs are needed.

Introduction

Congenital heart defects (CHDs) are structural malformations of the heart and/or the great intrathoracic vessels. They are the most frequent congenital malformation [1] and prevalence is estimated to be around 8-10 per 1,000 live births worldwide [1–4]. The most critical and severe defects, the major CHDs, (1-2 per 1,000 live births) have a serious impact on neonatal mortality and morbidity, and frequently result in neonatal heart failure or circulatory collapse requiring acute surgery [4]. However, other types of CHDs, like bicuspid aortic valve and transient septal heart defects, are far more frequent but of limited clinical significance.

The aetiology of CHDs is complex and poorly understood. An identifiable underlying cause (genetic and/or environmental) is present in 20-30% of CHDs [5]. Thus, 8-10% of CHDs can be attributed to chromosomal aberrations (e.g., DiGeorge syndrome, Down syndrome, Turner syndrome, etc.) [5,6]; while 5-15% may be the result of single-nucleotide or pathogenic copy number variants [5,7]. Additionally, viral infections in pregnancy (e.g., rubella), as well as exposure to certain teratogenic substances (e.g., alcohol or antiepileptic drugs) [8] may cause CHDs if the foetus is exposed at a critical point in development.

The normal pregnancy is an adaptive interplay between the maternal metabolism and foetal development. Differentiation of cardiac tissues begins in the third week of gestation, and by week eight, the foetal heart has undergone major changes, and will resemble the postnatal heart in structure and function [9]. Thus, the maternal-foetal interaction in the first two months of pregnancy is likely to be the most relevant window in time for a causative relation between maternal metabolism and CHDs. In first trimester, the foetus does not have the ability to secrete insulin, which may result in foetal hyperglycaemia in the event of relative maternal insulin resistance [10]. Animal models have shown that in embryos of chicks and rodents, exogenous glucose may cause a variety of malformations [11,12]. The significance of foetal hyperglycaemia has not been demonstrated in humans, but increasingly worse

glycaemic control around conception in women with diabetes type 1 (DM1) has recently been reported to be associated with a progressively increased risk of CHDs in the offspring [13].

Large cohort studies from Scandinavia and North America have reported an association between increased risk of CHDs and maternal metabolic disorders such as obesity [14,15], diabetes [16–18], hypertension [19,20], and preeclampsia (PE) [21,22]. All these metabolic disorders can be associated with hyperglycaemia and underlying insulin resistance, and thereby with the metabolic syndrome (MetS) [23,24]. There is a need to examine the evidence base for associations between combinations of maternal metabolic disorders, e.g. MetS, and CHDs. Either to complement existing knowledge or to define important new areas of research.

MetS includes a cluster of metabolic disorders in combination, usually any three of the following: abdominal obesity, insulin resistance, hypertension, and dyslipidaemia [23,25]. It is commonly reported to be a risk factor for diabetes type 2 (DM2) and cardiovascular disease in a non-pregnant population. Only a single multi-centre study from Australia, New Zealand and United Kingdom has assessed MetS in pregnant women and reported an incidence of 12.3% at 15 weeks' gestation [26] using the International Diabetes Federation criteria [25]. It is plausible that obesity, diabetes, hypertension, PE and dyslipidaemia as individual conditions, or more likely in combination, during pregnancy are expressions of insulin resistance and MetS [23,24]. Combinations of several maternal metabolic disorders in the same pregnancy (defined as obesity, diabetes, hypertension, PE, and dyslipidaemia), all related to MetS, are likely to be associated with higher risk of CHDs in the offspring as compared to women with a single disorder. The evidence base for an association between CHDs and combinations of metabolic disorders has not been systematically examined.

The aim of this systematic review is to evaluate the literature of associations between maternal metabolic disorders (obesity, diabetes, hypertension, PE, dyslipidaemia, or MetS) and particularly combinations thereof and CHDs in the offspring. The relation with overall occurrence of CHDs as well as CHDs broken down into individual subtypes. Since these maternal metabolic disorders likely persist over time, they may be relevant for the risk of CHDs in subsequent pregnancies. Furthermore, we examined the extent to which recent reviews have mentioned the possibility of combined maternal disorders. On this background, we will point to gaps in current knowledge and make recommendations for future research possibly paving the way to improved prevention of CHDs.

Materials and methods

Search strategy

Following the Systematic Reviews and Meta-Analyses (PRISMA) checklist (S1 Appendix), a systematic literature search of papers published between January 1, 1990 and October 6, 2019 was conducted using PubMed and Embase. MetS was initially described by G.M. Reaven in 1988 as an "insulin resistance syndrome" [27], and the literature search was limited to publications focussing on its role in CHDs. The search strategy used keywords that combined CHDs and pregnancies with maternal metabolic disorders (obesity, diabetes, hypertension, PE, dyslipidaemia and/or MetS). Although DM1 is not a part of the MetS, it was included in the review as a metabolic disorder because the associated hyperglycaemia is known to be associated with CHDs. More details about the literature search can be found in S1 Table. Subsequently, reference lists from the individual papers were reviewed for additional relevant studies.

Exposures, outcomes and definitions

The exposures of interest were maternal overweight and obesity, diabetes (DM1, DM2 or gestational diabetes (GDM)), hypertension, PE, dyslipidaemia, and/or MetS during pregnancy. Maternal body mass index (BMI) (weight in kilograms divided by the square of the height in meters (kg/m^2)) was defined as pre-pregnancy or early-pregnancy BMI measured in first trimester. The outcome of interest was CHDs defined as structural malformations of the heart chambers, heart valves, great arteries and septal defects, corresponding to DQ20-26 in the World Health Organization International Classification of Diseases (ICD-10) or diagnoses referable to these. The CHD diagnoses are described as "any CHDs" for the whole group of heart defects (only including studies that explicitly listed their definition thereof), "major CHDs" for a group of the most critical and severe CHD diagnoses or as CHD subtypes in relation to the maternal disorders. Studies could include both singleton and multiple births.

Eligibility criteria

Two different authors (GH, PLH and/or INT) screened all titles and abstracts individually. Studies were initially eligible if they met the following criteria: 1. Studies were published in English; 2. Studies were case-control or cohort studies; 3. The exposures of interest were maternal overweight or obesity, hypertension, PE, diabetes, dyslipidaemia, and/or MetS; and 4. The outcome of interest was CHDs in the offspring.

Quality assessment

One author (GH) conducted the study selection and quality assessment based on a full-text review. Any doubts were resolved by discussion with at least one co-author. The Newcastle-Ottawa Scale was used to assess the quality of eligible studies [28]. Using this tool (S2 Table), each study was judged on three categories: 1. selection of cohorts or cases and controls; 2. comparability of cohorts or cases and controls on the basis of the design or analysis; and 3. ascertainment of outcome or exposure. Highest quality studies could be awarded nine stars. If a study received seven or more stars (S3 Table), it was considered of high methodological quality and included in the review [28]. Studies were excluded if they had less than 15 CHD cases in total. In consequence, some studies will only contain few cases of each CHD subtype.

Data was extracted to figures without processing results. Results are presented as odds ratios (OR), risk ratios (RR) or prevalence ratios (PR) with 95% confidence interval (CI). Results are presented adjusted (aOR/aRR/aPR) for pertinent possible confounding factors, if accessible.

Results

Study identification and selection

140 The selection of studies is described in Fig 1. In the event of multiple publications using the same data, we included
141 the study that provided the most comprehensive information. A total of 30 publications were included in the review
142 (Table 1 and S3 Table). Among these, 15 dealt with maternal overweight or obesity [14,15,19,29–40], nine dealt with
143 pre-gestational diabetes (PGDM) [16–18,40–45], four dealt with DM1 [13,19,46,47], two dealt with DM2 [19,46],
144 seven dealt with GDM [16–18,39,40,44,47], four dealt with hypertension [19,20,41,46], three dealt with PE [21,22,48],
145 and none were about dyslipidaemia or MetS (as a diagnostic category). Except for the combination of PGDM and
146 GDM, five studies investigated more than one maternal metabolic disorder (but not in combination) [19,39–41,46],
147 and one study assessed a combination of two conditions (obesity and GDM) and the risk of CHDs [31].

148

149 **Fig 1. Flow diagram.** The process of selection of studies that were included in the review. Literature search included
150 studies published from January 1, 1990 to October 6, 2019. Abbreviations: CHDs, congenital heart defects; ICD,
151 International Classification of Disease; NOS, Newcastle-Ottawa Scale

152

153 **Table 1. Summary table of characteristics of included studies**

Characteristics	Range of values
Year of publication	1991-2019
Country of study population	North America (n=15), Europe (n=12), Other countries (n=3)
Study design	Cohort (n=17), Case-control (n=13)
Population size	Cohorts (41 013 - 4 207 898), Case-controls (525 - 1 124 370)
Cases with CHDs	Cohorts (233 - 48 249), Case-controls (35 - 10 625)
Included study population	Only live births (n=15); Live births + stillbirths (n=8); Live births + stillbirths + terminated pregnancies (n=7)
Plurality	Singletons (n=13), All (n=8), Not stated (n=9)
Maternal exposure	Obesity (n=15), PGDM (n=9), DM1 (n=4), DM2 (n=2), GDM (n=7), hypertension (n=4), PE (n=3), obesity+GDM (n=1)

Sources of maternal exposure	Registers (n=18), interviews (n=9), medical records (n=2), questionnaire+medical records (n=1)
Studies of each CHD subtype	Heterotaxia (n=9), UVH (n=6), Conotruncal defects (n=8), Common truncus (n=7), TGA (n=20), ToF (n=20), DORV (n=3), Aortic arch defects (n=1), AVSD (n=17), TAPVR (n=8), LVOT (n=9), HLHS (n=12), CoA (n=14), Aortic stenosis (n=8), RVOT (n=9), Pulmonary valve stenosis (n=8), Ebstein's anomaly (n=5), Septal defects (n=6), ASD (n=21), VSD (n=18)
Newcastle-Ottawa Scale (NOS) score	7 – 8

A more comprehensive version of the table is available as S3 Table. Details on NOS score can be seen in S2 Table. Abbreviations: ASD, atrial septal defects; AVSD, atrioventricular septal defects; CoA, coarctation of the Aorta; DM1, diabetes type 1; DM2, diabetes type 2; DORV, double outlet right ventricle; GDM, gestational diabetes; HLHS, hypoplastic left heart syndrome; LVOT, left ventricular outflow tract defects; PE, preeclampsia; PGDM, pre-gestational diabetes; RVOT, right ventricular outflow tract defects; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great arteries; ToF, Tetralogy of Fallot; UVH, univentricular heart; VSD ventricular septal defects.

Study characteristics

The 30 included studies consisted of 17 cohort studies and 13 case-control studies. Characteristics of the 30 studies are presented in Table 1 and S3 Table. Two examined populations of non-European descent (Taiwan and China) [39,46]. Half of the studies reported results from livebirths only; eight studies had populations including both singleton and multiple births; and nine studies did not state whether they included only singleton or multiple births. Associations between maternal metabolic disorders and CHDs are illustrated in Fig 2 (any CHDs) and S1-S20 Figs (CHD subtypes). All 30 studies were assessed using the Newcastle-Ottawa Scale and were required to be of high methodological quality (S2 Table and S3 Table). Study designs were heterogeneous, particularly regarding the definition and categorization of the maternal metabolic disorders.

171 **Fig 2. Maternal metabolic disorders and risk of any congenital heart defect in the offspring.** Any CHDs defined as the
172 whole group of heart defects (only including studies that explicitly listed their definition thereof). Obesity is defined as
173 BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as diagnosed before gestational week 34; and PGDM are
174 defined as DM1 or DM2. All risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤,
175 obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; ¥, BMI ≥ 28 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated
176 hypertension; ‡, estimate only for severe CHDs; @, results from singleton pregnancies. Abbreviations: BMI, body mass
177 index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia;
178 PGDM, pre-gestational diabetes; PR, prevalence ratio; RR, risk ratio.

179

180 Maternal overweight or obesity and CHDs in the offspring

181 Several studies have investigated the association between maternal overweight or obesity and any CHDs
182 [14,15,19,31,33,37,49]. In Fig 2, four out of seven studies found a significant association between maternal obesity
183 (BMI ≥ 30 kg/m^2) and any CHDs. Three of them reported higher risk estimates for any CHDs with higher maternal BMI:
184 RR 1.07 (BMI 25-29.9 kg/m^2) and RR 1.60 (BMI ≥ 40 kg/m^2) [14]; aOR 1.15 (BMI 25-29.9 kg/m^2) and aOR 1.34 (BMI ≥ 40
185 kg/m^2) [15]; and aOR 1.16 (BMI 25-29.9 kg/m^2) and aOR 1.31 (BMI ≥ 35 kg/m^2) [31]. The fourth study only reported an
186 association between maternal obesity diagnosed as ICD-10 codes and any CHDs, and did not assess the risk in relation
187 to BMI categories [19]. Three studies found no significant association between any CHDs in the offspring and maternal
188 overweight or obesity [33,37,49].
189 Most studies investigated specific CHD subtypes in relation to maternal BMI, these results are presented for maternal
190 obesity (BMI ≥ 30 kg/m^2) in S1-S20 Figs and summarized in Table 2. Some studies found significant associations
191 between obesity and 13 CHD subtypes, however, other studies did not find a significant association.

192

193 **Table 2. Overview of association between congenital heart defect subtypes and maternal exposures.**

	Obesity	PGDM	DM1	DM2	GDM	Hypertension	PE (early-onset)	Obesity + GDM
Heterotaxia	2↓	3(**2**)↑	1↑	1(**1**)↑	2↑	1↑ 1↓	2(**1**)↑ 1↓	1↑
UVH	2↑	2(**1**)↑	NA	NA	1↑	1↑ 1↓	1(**1**)↑	1↓
Conotruncal defects	4(**2**)↑ 1↓	3(**2**)↑	1(**1**)↑	1(**1**)↑	1↑	2(**1**)↑	1(**1**)↑	1↑
Common truncus	1↑	3(**2**)↑	NA	NA	1(**1**)↑	2(**1**)↑	1(**1**)↑	NA
TGA	8(**2**)↑ 3↓	6(**3**)↑	NA	NA	2↑	2↓	2↓	1↓
ToF	7(**3**)↑ 4↓	5(**4**)↑	NA	NA	2(**1**)↑	2(**1**)↑	1↑ 1↓	1(**1**)↑
DORV	1↑	1(**1**)↑	NA	NA	NA	NA	1(**1**)↑	NA
Aortic arch defects	1(**1**)↑	NA	NA	NA	NA	NA	NA	NA
AVSD	6(**2**)↑	6(**5**)↑	1(**1**)↑	1(**1**)↑	3(**1**)↑ 1↓	3(**2**)↑	3(**3**)↑	1↑
TAPVR	1↑ 1↓	4(**2**)↑	NA	NA	1(**1**)↑ 1↓	1↓	1(**1**)↑	1↑
LVOT	2(**1**)↑ 2↓	4(**4**)↑	1(**1**)↑	1(**1**)↑	2(**1**)↑	1↑	1↓	1(**1**)↑
HLHS	5(**2**)↑ 1↓	3(**1**)↑	NA	NA	1↑ 1↓	1↑ 1↓	1↑ 1↓	1(**1**)↑
CoA	5↑ 1↓	5(**3**)↑	NA	NA	2(**1**)↑	1(**1**)↑ 1↓	2↑	1↑
Aortic stenosis	2(**1**)↑ 1↓	4(**3**)↑	NA	NA	1(**1**)↑ 1↓	1↑ 1↓	NA	1↑
RVOT	3(**2**)↑ 1↓	4(**3**)↑	1↑	1↑	2(**1**)↑	1(**1**)↑	1(**1**)↑	1(**1**)↑
Pulmonary valve stenosis	4(**2**)↑	3(**2**)↑	NA	NA	2(**1**)↑	1(**1**)↑	NA	1(**1**)↑

Ebstein's anomaly	1↑	1(**1**)↑	NA	NA	1↑	2↑	1↑	NA
Septal defects	3(**1**)↑	2(**2**)↑	NA	NA	1(**1**)↑	NA	1(**1**)↑	1(**1**)↑
VSD	10(**3**)↑	7(**5**)↑	1(**1**)↑	1(**1**)↑	2(**1**)↑	3(**3**)↑	3(**3**)↑	1↑
ASD	9(**6**)↑	5(**3**)↑ 1↓	1(**1**)↑	1(**1**)↑	2(**1**)↑	2(**2**)↑ 1↓	2(**2**)↑	1(**1**)↑

Numbers reflect number of studies examining specific combinations of CHD subtype and exposure. Numbers of significant associations are given in bold and brackets. Arrows reflect positive (↑) and negative (↓) directions of the associations. The individual studies are detailed in S1-S20 Figs. Abbreviations: ASD, atrial septal defects; AVSD, atrioventricular septal defects; CoA, coarctation of the Aorta; DM1, diabetes type 1; DM2, diabetes type 2; DORV, double outlet right ventricle; GDM, gestational diabetes; HLHS, hypoplastic left heart syndrome; LVOT, left ventricular outflow tract defects; PE, preeclampsia; PGDM, pre-gestational diabetes; RVOT, right ventricular outflow tract defects; TAPVR, total anomalous pulmonary venous return; TGA, transposition of the great arteries; ToF, Tetralogy of Fallot; UVH, univentricular heart; VSD ventricular septal defects.

Maternal pre-gestational diabetes and CHDs in the offspring

Most studies defined PGDM as either DM1 or DM2 (S3 Table). Only four studies assessed DM1 or DM2 individually [13,19,46,47]. Seven studies found a strong significant association with any CHDs (Fig 2), irrespective of the type of diabetes investigated, PGDM [16–18,44], DM1 [13,19,46], or DM2 [19,46].

Two studies presented associations between PGDM and major CHDs, but they defined major CHDs differently: Leirgul et al. found an association between PGDM and major CHDs (aRR 3.34, CI 2.48-4.49) [18], and Chou et al. found an association between DM2 and major CHDs (aOR 2.80, CI 2.04-3.85), but did not find a significant association between DM1 and major CHDs (aOR 0.73, 0.10–5.32) [46].

Several studies have investigated the relationship between PGDM, DM1 or DM2 and specific CHD diagnoses [16–19,40–45,47] and in many cases found a strong significant association (S1-S20 Figs and Table 2).

Maternal gestational diabetes and CHDs in the offspring

Five studies reported an association between GDM and any CHDs [16–18,39,44], but only the results from four of them are shown in Fig 2. The last study by Øyen et al. found an association between any CHDs and GDM diagnosed in the third trimester (aRR 1.36; CI 1.07-1.69), but did not find a significant association between any CHDs and GDM diagnosed in the second trimester [16]. Five studies reported a weak association between GDM and some subtypes of CHDs (S1-S20 Figs and Table 2).

Maternal chronic hypertension and CHDs in the offspring

Two large cohort studies from Canada and Taiwan reported a significant association between maternal pre-existing chronic hypertension and any CHDs (Fig 2) [19,46]. Two studies assessed the association between subtypes of CHDs and chronic hypertension [19,41], (S1-S20 Figs), but associations were inconsistent. None of the three studies mentioned reported on potential antihypertensive drug use by the mothers. An American case-control study with

10,625 cases with CHDs found a significant association between untreated hypertension and any CHDs (Fig 2) as well as for five subtypes of CHDs (S1-S20 Figs and Table 2) [20].

Maternal preeclampsia or gestational hypertension and CHDs in the offspring

Three studies investigated associations between PE and any CHDs or major CHDs. Although the definition of PE varied among the studies, all studies defined early-onset PE as diagnosed before gestational week 34, and the association with any CHDs can be seen in Fig 2. Pregnancies with PE were associated with any CHDs (PR 1.57, CI 1.48-1.67) [22], and early-onset PE was associated with major CHDs (aRR 2.7, CI 1.3-5.6 [48], and aPR 3.64, CI 2.17-6.10 [22]), all compared to normotensive pregnancies.

Weaker associations, between PE and any CHDs, were reported when PE was diagnosed later in pregnancy: PE with delivery at 34 to 36 weeks (OR 2.82, CI 2.38-3.34) [21]; PE at term (OR 1.16, CI 1.06-1.27) [21]; and late-onset PE (> 34 weeks' gestation) (aPR 1.14, CI 1.06-1.23) [22]. Furthermore, Boyd et al. did not find an association between gestational hypertension and any CHDs [21]. The studies also assessed subtypes of CHDs and their association with early-onset PE, which are illustrated in S1-S20 Figs and summarized in Table 2, especially atrioventricular septal defects (S9 Fig) and atrial septal defects (S19 Fig) were strongly associated with early-onset PE.

Risk of CHDs in the offspring in subsequent pregnancies

Two studies assessed PE and CHDs, and potential risks of both in subsequent pregnancies [21,48]. While, Brodwall et al. did not find an association between PE and CHDs across pregnancies [48], Boyd et al. reported a much higher risk of having a child with CHDs in subsequent pregnancies after a pregnancy with PE and delivery before 34 weeks' gestation (OR 7.91, CI 6.06-10.3). Boyd et al. also found an association between a previous pregnancy with a child with CHDs and increased risk of PE with delivery before 34 weeks' gestation in subsequent pregnancies (OR 2.37; CI 1.68-

3.34) [21]. Studies on the other maternal metabolic disorders did not comprise an analysis of risks in subsequent pregnancies.

Combination of maternal obesity and gestational diabetes and CHDs in the offspring

Only one study comprised an assessment of the risk associated with pregnancies affected by two maternal metabolic conditions. Gilboa et al. reported a possible additive effect of the combination of maternal obesity (BMI ≥ 30 kg/m^2) and GDM and the risk of any CHDs compared to only obesity (aOR 1.82 vs. 1.31) [31]. The relation between the combination of maternal obesity and GDM and subtypes of CHDs are reported in S1-S20 Figs and summarized in Table 2 showing a significant association for six subtypes of CHDs.

Trends in associations of specific CHD subtypes

As shown in Table 2, there are no clear differences in the direction of associations between CHD subtypes and individual maternal metabolic disorders. Of note is that none of the studies, suggesting reduced risk of CHD was statistically significant.

Recent reviews

Systematic reviews and meta-analyses further documented the associations for some of the individual maternal metabolic disorders: obesity [50–52], diabetes [17,53,54], and hypertension [55]. However, only a single review mentioned combinations of GDM and obesity, citing only two studies [56]. No reviews sought to estimate the effect of simultaneous presence of several metabolic disorders.

Discussion

Main findings

The associations between any CHDs and maternal metabolic disorders fall in three groups: A. chronic hypertension, GDM, and obesity with OR/RR/PR of 1.2-1.9; B. PGDM with OR/RR/PR around 3-4; and C. early-onset PE with OR/RR/PR of 5-7. Thus, for the most prevalent maternal conditions, the associated risks of CHDs are only marginally elevated. Although maternal obesity is associated with higher risk of GDM, DM2, hypertension, PE, and dyslipidaemia [57], no studies assessing the association between CHDs in the offspring and the combination of all maternal metabolic disorders were identified, and only one study dealt with the combination of two maternal metabolic conditions (obesity and GDM) as risk factor for CHDs in the offspring [31]. All other studies investigated the individual metabolic disorders and their association with CHDs, and there were no eligible studies on dyslipidaemia. Overall, those studies found a significant association between any CHDs and obesity, PGDM, GDM, hypertension, or early-onset PE, respectively (Fig 2). Contradictory evidence of associations with subtypes of CHDs were noted for most maternal conditions, with the exception of early-onset PE, which was strongly associated with both atrioventricular septal defects (S9 Fig) and atrial septal defects (S19 Fig); and PGDM which was strongly associated with most subtypes (S1-S20 Figs).

Early-onset PE was strongly associated with a higher risk of having a child with CHD in subsequent pregnancies, studies on the other maternal metabolic disorders did not approach risks in subsequent pregnancies.

There was no discernible pattern of associations between CHD subtypes and metabolic disorders (Table 2). However, the number of studies for many of the combinations is very small.

Aetiological considerations and possible prevention of CHDs

Relation between maternal metabolic disorders and foetal heart development

There is a clear pathophysiological connection between maternal insulin resistance and foetal CHDs, with glucose-mediated mechanisms of CHD involving multiple developmental pathways [58]: comprise left-right patterning [59], alterations in neural crest cells migration and formation [60,61], increased apoptosis [62,63] as well as changes in nitric oxide signalling [64], and impaired autophagy [65]. All these mechanisms may cause or modify the development of CHDs. The investigated maternal metabolic disorders (obesity, diabetes, hypertension, preeclampsia, dyslipidaemia, and MetS) are all linked to insulin resistance and/or hyperglycaemia [24,66]. The finding of the same association for these conditions as for DM1 [16] justifies a particular focus on the role of aberrations in the glucose-insulin homeostasis. Obesity, DM1, DM2, chronic hypertension, and dyslipidaemia are present prior to conception and therefore affect maternal metabolism and foetal development during the essential first two months of pregnancy. However, PE and GDM are per definition not diagnosed before mid-pregnancy [67,68], but it is likely that subclinical metabolic alterations emerge at a much earlier stage. It can be challenging to distinguish GDM from PGDM since most women are not screened for diabetes before pregnancy, and up to 50% of women diagnosed with GDM develop DM2 within five years after giving birth [69]. So it is plausible that many women with GDM might already be insulin resistant without it being detectable in first trimester. This is particularly challenging because fasting and postprandial glucose concentrations are normally lower in the early part of pregnancy (e.g., first trimester and first half of second trimester) than in normal, non–pregnant women [68]. Insulin resistance is more pronounced early in pregnancies with PE compared to pregnancies without PE [24,70]. In first trimester pregnancies that later develop PE are characterised by changes in IGF-axis markers, e.g. PAPP-A, and ProMBP [71,72], placental proteins [73], and adipokines, e.g. leptin and adiponectin [74,75], indicating that the clinical presentation of PE is preceded by a foeto-maternal dyscrine condition. The fact that the nutritional status of the foetus influences the risk of cardiovascular disease in adulthood (Barker Hypothesis) [76] - also indicates that placental function may play a role in the aetiology of foetal malformations. There is a need to identify particular pathways where perturbations, especially in the glucose-insulin axis, cause specific malformations, but such studies will have to be large as some of the malformations are fairly rare and the molecular aetiology likely heterogeneous.

Possible teratogenic effect of medication

Women with chronic hypertension or DM1 will most likely be undergoing medical treatment as well as some women with DM2 will be treated with antidiabetic drugs. Some of these drugs might have a teratogenic effect and by not taking them into considerations in the studies, they could influence the estimates of association. It is thus important to distinguish between the effects of the drugs and the conditions proper. Insulin is not believed to be teratogenic [77], suggesting that the focus should be on the insulin resistance and the glucose levels. Observational studies suggest that exposure to either metformin or beta-blockers during pregnancy may actually increase the risk of certain types of CHDs in the foetus [20,78]. A meta-analysis by Ramakrishnan et al. observed an association between untreated hypertension and CHDs, which suggests that the association between hypertension and CHDs is not simply due to teratogenic effects of medication alone, but the effect was larger for treated hypertension [55]. Thus, antihypertensive medications may lead to an additional increase in risk, but it might also just indicate a more severe disease in the mother.

Prevention of CHDs in the offspring

It is very well-established that maternal obesity is associated with marginally increased risk of CHDs, and two meta-analyses reported a dose-response effect on risk of CHDs with increasing BMI [52,79]. But an increase of 20-40% of a very small risk in general may not be clinically significant. Particularly as it has not yet been shown that weight reduction normalizes the risk and a study showing such an effect would be complicated and difficult to perform. Future studies investigating the prevalence of CHDs in obese pregnant women could compare women who had undergone bariatric surgery with a control group as well as risk in pregnancies before and after the surgery as it has been done in studies on birth weight and obesity in childhood [80,81]. The Swedish cohort study of 1.2 million pregnant women with DM1 showed that poor glycaemic control around conception was associated with a progressively higher risk of CHDs in the offspring [13]. PGDM and early-onset PE have a strong association with CHDs, however, the clinical significance of preventive measures has not been established.

Heterogeneity in studies

Comparison of results from different studies in this review was hampered by heterogeneity. This is due to several factors: 1. Case-control studies provide estimates of risk that may be less valid and reliable than prospective, population-based cohort studies for estimating occurrence of CHDs– i.e., for some subtypes of CHDs, the cohort studies find a significant association while the results from the case-control studies are insignificant. 2. The studies assessing maternal obesity and CHDs often excluded pregnancies with PGDM, whereas others did not and are therefore difficult to compare; studies on obesity usually also divided maternal BMI into categories that distinguished them from a direct comparison with another study. 3. Diagnostic criteria for PGDM and GDM were not always explained. 4. Not all studies include stillbirths and terminated pregnancies, which could skew the results, i.e., the risk of CHDs in live born offspring of women with obesity relative to women without obesity might be overestimated, since it is well-known that congenital malformations are more difficult to detect by prenatal ultrasound in these women and they are therefore not necessarily given the possibility to terminate the pregnancy in case of a severe malformation [82]. 5. Studies on both singleton and multiple births without distinguishing between them may add to the heterogeneity because the risk of CHDs is higher in multiple birth [83].

We presented adjusted risks and compared them although the studies did not all adjust for the same confounders. Many studies adjust for maternal age, parity and year of birth, while others also adjust for race/ethnicity, education, smoking, marital status etc. Even though not always available, we could have presented crude risks, however, we believe that the adjusted risks represent the best possible estimate since results otherwise would have been known to be biased.

Significance of genetic aetiology

The aetiology of CHD is complex and the important breakthroughs in next generation sequencing of whole genomes as well as implementation of chromosomal micro arrays have as of now led to the identification of a strong genetic component in 15-20% of CHD cases [5]. The genetic aetiology ranges from chromosomal disorders over micro-deletions to copy number variants and single-gene disorders. Many of the genetic causes of CHDs are characterized by extensive phenotypic variability and a broad spectrum of comorbidities [5]. Thus, some cases of e.g. Williams syndrome [84] as well as Bardet-Biedl syndrome [85] exhibit malformations in combinations with obesity, DM2, and

hypertension. In cases where the mother carries genetic variants that cause or pre-dispose to such conditions, the association between CHDs and maternal metabolic disorders might be one of common aetiology (horizontal pleiotropy) rather than one of a causal relation between maternal conditions and the development of CHDs (vertical pleiotropy). With further advances in genetic characterization of CHDs, one might see a more detailed understanding of the extent of comorbidities in CHD-associated genetic disorders. This phenomenon might bias the association analysis.

Strengths and limitations

The strength of this review is that we have selected only high-quality, original research studies from a systematic literature search. However, we have limited our selection of studies to those published in English and from 1990 and after, which may have excluded a number of high-quality studies, which were published in another language or before 1990. However, the screening of the references of the articles included did not reveal relevant studies published before 1990. Furthermore, our review did not include meta-analyses as prescribed by PRISMA since we found the data too heterogeneous to summarize in a meta-analysis. Finally, it should be remembered that some CHD subtypes are very rare, resulting in very broad confidence intervals in association analyses.

Perspectives

The global birth prevalence of CHDs has increased by 10% every five years between 1970 and 2017, which probably is due to increased detection of milder lesions [2]. The incidence of MetS often parallels the incidence of obesity, which has nearly tripled worldwide since 1975 [86], and Centers for Disease Control and Prevention estimated that 40% of women aged 20-39 years old in the United States had a BMI ≥ 30 kg/m^2 in 2017-2018 [87]. Maternal obesity and dyslipidaemia increases the risk of developing both PE and GDM [88,89], GDM closely associated with risk of DM2, PE increases the risk of future chronic hypertension [90], and studies indicate that women with PE have increased risk of insulin resistance later in life [91]. So, the maternal metabolic disorders might be related to later MetS (except for

392 DM1), and all components are associated with CHDs in offspring – either individually or with an additive effect. Our
393 analysis shows that there is a remarkable lack of knowledge on several aspects of the link between maternal
394 metabolic disorders and CHDs in the offspring. Large population-based studies are needed to identify possible
395 synergistic effects. Indeed, the combination may have a greater impact than each individual factor and result in
396 amplified risk of CHDs – also taking into consideration at what time the maternal metabolic disorder develops in
397 relationship to the development of the foetal heart. Furthermore, such studies should be ethnically inclusive, and also
398 include women of different socio-economic status. There is also a need for more detailed studies of the molecular
399 mechanisms of CHDs, especially regarding the possibly common underlying pathophysiological mechanisms, insulin
400 resistance and glucose-insulin homeostasis in particular, and their genomic basis. A combination of such studies in
401 carefully investigated cohorts and the use of electronic health records in a population-wide biobank setting could
402 bring relevant knowledge on mechanisms that might pave the way to preventive approaches to CHDs. Furthermore, it
403 is important to examine whether a modification of a pre-existing condition influences risks for CHDs.

404

405 # Conclusion

406 CHDs are the most common malformations and a major cause of morbidity and mortality in childhood. Although the
407 aetiology is complex, it is important to identify risk factors in order to pave the way for targeted prevention of CHDs.
408 Our review shows that there is a well-established association, albeit to a varying extent, between individual maternal
409 metabolic disorders such as obesity, diabetes, hypertension, and PE with increased risk of CHDs in the child. However,
410 the evidence base for association between combinations of maternal metabolic disorders and CHDs was found to be
411 very small. Since occurrence of MetS is rapidly increasing, there is a need for such studies. Secondly, there is a need
412 for large studies based on genetically characterized CHD cases, where the association with MetS could be an
413 expression of comorbidity involving both CHDs and maternal metabolic disorders implying aberrations of the glucose-
414 insulin homeostasis. Thirdly, there is a need for studies covering populations other than those of European and Asian
415 descent, particularly as the prevalence of MetS and its different manifestations vary widely around the globe. Such
416 studies may result in the identification of subgroups of women, in whom MetS might be of particularly importance as

a risk factor. Finally, it is important to examine whether preventive actions against pre-pregnancy maternal metabolic disorders influences the risk of CHDs.

Acknowledgements

Thank you to the researchers who readily provided supplementary information. This research has been conducted using the Danish National Biobank resource supported by the Novo Nordisk Foundation.
An earlier version of the article is available at a preprint server, MedRxiv (DOI: https://doi.org/10.1101/2020.06.25.20140186).

Abbreviations

CHDs, congenital heart defects; MetS, metabolic syndrome; PE, preeclampsia; BMI, body mass index; GDM, gestational diabetes; DM2, diabetes type 2; DM1, diabetes type 1; ICD-10, International Classification of Diseases, 10th revision; OR, odds ratio; RR, risk ratio; PR, prevalence ratio; CI, 95% confidence interval; PGDM, pre-gestational diabetes.

References

1. Dolk H, Loane M, Garne E, European Surveillance of Congenital Anomalies (EUROCAT) Working Group. Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation. 2011;123: 841–849. doi:10.1161/CIRCULATIONAHA.110.958405

2. Liu Y, Chen S, Zühlke L, Black GC, Choy M, Li N, et al. Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol. 2019;48: 455–463. doi:10.1093/ije/dyz009

3. van der Linde D, Konings EEM, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJM, et al. Birth Prevalence of Congenital Heart Disease Worldwide. J Am Coll Cardiol. 2011;58: 2241–2247. doi:10.1016/j.jacc.2011.08.025

4. Lytzen R, Vejlstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK, et al. Live-Born Major Congenital Heart Disease in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. JAMA Cardiol. 2018;3: 829–837. doi:10.1001/jamacardio.2018.2009

5. Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, et al. Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association. Circulation. 2018;138: e653–e711. doi:10.1161/CIR.0000000000000606

6. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The changing epidemiology of congenital heart disease. Nat Rev Cardiol. 2011;8: 50–60. doi:10.1038/nrcardio.2010.166

7. Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49: 1593–1601. doi:10.1038/ng.3970

8. Hoffman JIE. Epidemiology of congenital heart disease: etiology, pathogenesis, and incidence. In: Yagel S, Silverman NH, Gembruch U, editors. Fetal Cardiology: Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of Cardiac Diseases. 2nd ed. Taylor & Francis; 2009. pp. 101-110.

456 9. Wenink ACG. Cardiovascular development. In: Yagel S, Silverman NH, Gembruch U, eds. Fetal Cardiology:
457 Embryology, Genetics, Physiology, Echocardiographic Evaluation, Diagnosis and Perinatal Management of
458 Cardiac Diseases. 2nd ed. Taylor & Francis; 2009. pp. 1-8.

459 10. Rorsman P, Arkhammar P, Bokvist K, Hellerström C, Nilsson T, Welsh M, et al. Failure of glucose to elicit a
460 normal secretory response in fetal pancreatic beta cells results from glucose insensitivity of the ATP-regulated
461 K+ channels. Proc Natl Acad Sci U S A. 1989;86: 4505–4509. doi:10.1073/pnas.86.12.4505

462 11. Hughes AF, Freeman RB, Fadem T. The teratogenic effects of sugars on the chick embryo. J Embryol Exp
463 Morphol. 1974;32: 661–674.

464 12. Garnham EA, Beck F, Clarke CA, Stanisstreet M. Effects of glucose on rat embryos in culture. Diabetologia.
465 1983;25: 291–295. doi:10.1007/BF00279946

466 13. Ludvigsson JF, Neovius M, Söderling J, Gudbjörnsdottir S, Svensson A-M, Franzén S, et al. Periconception
467 glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study
468 in Sweden. BMJ. 2018;362: k2638. doi:10.1136/bmj.k2638

469 14. Persson M, Razaz N, Edstedt Bonamy A-K, Villamor E, Cnattingius S. Maternal Overweight and Obesity and Risk
470 of Congenital Heart Defects. J Am Coll Cardiol. 2019;73: 44–53. doi:10.1016/j.jacc.2018.10.050

471 15. Brite J, Laughon SK, Troendle J, Mills J. Maternal overweight and obesity and risk of congenital heart defects in
472 offspring. Int J Obes 2005. 2014;38: 878–882. doi:10.1038/ijo.2013.244

473 16. Øyen N, Diaz LJ, Leirgul E, Boyd HA, Priest J, Mathiesen ER, et al. Prepregnancy Diabetes and Offspring Risk of
474 Congenital Heart Disease: A Nationwide Cohort Study. Circulation. 2016;133: 2243–2253.
475 doi:10.1161/CIRCULATIONAHA.115.017465

476 17. Hoang TT, Marengo LK, Mitchell LE, Canfield MA, Agopian AJ. Original Findings and Updated Meta-Analysis for
477 the Association Between Maternal Diabetes and Risk for Congenital Heart Disease Phenotypes. Am J Epidemiol.
478 2017;186: 118–128. doi:10.1093/aje/kwx033

479 18. Leirgul E, Brodwall K, Greve G, Vollset SE, Holmstrøm H, Tell GS, et al. Maternal Diabetes, Birth Weight, and
480 Neonatal Risk of Congenital Heart Defects in Norway, 1994-2009. Obstet Gynecol. 2016;128: 1116–1125.
481 doi:10.1097/AOG.0000000000001694

482 19. Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, et al. Association between maternal chronic
483 conditions and congenital heart defects: a population-based cohort study. Circulation. 2013;128: 583–589.
484 doi:10.1161/CIRCULATIONAHA.112.001054

485 20. Fisher SC, Van Zutphen AR, Werler MM, Lin AE, Romitti PA, Druschel CM, et al. Maternal Antihypertensive
486 Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention
487 Study. Hypertens Dallas Tex 1979. 2017;69: 798–805. doi:10.1161/HYPERTENSIONAHA.116.08773

488 21. Boyd HA, Basit S, Behrens I, Leirgul E, Bundgaard H, Wohlfahrt J, et al. Association Between Fetal Congenital
489 Heart Defects and Maternal Risk of Hypertensive Disorders of Pregnancy in the Same Pregnancy and Across
490 Pregnancies. Circulation. 2017;136: 39–48. doi:10.1161/CIRCULATIONAHA.116.024600

491 22. Auger N, Fraser WD, Healy-Profitós J, Arbour L. Association Between Preeclampsia and Congenital Heart
492 Defects. JAMA. 2015;314: 1588–1598. doi:10.1001/jama.2015.12505

493 23. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr
494 Rev. 2008;29: 777–822. doi:10.1210/er.2008-0024

495 24. Jeyabalan A, Hubel CA, Roberts JM. Metabolic Syndrome and Preeclampsia. In: Taylor RN, Roberts JM,
496 Cunningham FG, Lindheimer MD, eds. Chesley's Hypertensive Disorders in Pregnancy. 4th ed. Academic Press;
497 2015. pp. 133-160.

498 25. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.
499 Obes Rev Off J Int Assoc Study Obes. 2015;16: 1–12. doi:10.1111/obr.12229

500 26. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, Leemaqz SY, Poston L, McCowan LM, et al. Metabolic syndrome in
501 pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women. PLoS Med.
502 2018;15: e1002710. doi:10.1371/journal.pmed.1002710

503 27. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37: 1595–1607.
504 doi:10.2337/diab.37.12.1595

505 28. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for
506 assessing the quality of nonrandomised studies in meta-analyses. Available from:
507 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

508 29. Block SR, Watkins SM, Salemi JL, Rutkowski R, Tanner JP, Correia JA, et al. Maternal pre-pregnancy body mass
509 index and risk of selected birth defects: evidence of a dose-response relationship. Paediatr Perinat Epidemiol.
510 2013;27: 521–531. doi:10.1111/ppe.12084

511 30. Blomberg MI, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. Birt
512 Defects Res A Clin Mol Teratol. 2010;88: 35–40. doi:10.1002/bdra.20620

513 31. Gilboa SM, Correa A, Botto LD, Rasmussen SA, Waller DK, Hobbs CA, et al. Association between prepregnancy
514 body mass index and congenital heart defects. Am J Obstet Gynecol. 2010;202: 51.e1-51.e10.
515 doi:10.1016/j.ajog.2009.08.005

516 32. Mills JL, Troendle J, Conley MR, Carter T, Druschel CM. Maternal obesity and congenital heart defects: a
517 population-based study. Am J Clin Nutr. 2010;91: 1543–1549. doi:10.3945/ajcn.2009.28865

518 33. Rankin J, Tennant PWG, Stothard KJ, Bythell M, Summerbell CD, Bell R. Maternal body mass index and
519 congenital anomaly risk: a cohort study. Int J Obes 2005. 2010;34: 1371–1380. doi:10.1038/ijo.2010.66

520 34. Shaw GM, Carmichael SL. Prepregnant obesity and risks of selected birth defects in offspring. Epidemiol Camb
521 Mass. 2008;19: 616–620. doi:10.1097/EDE.0b013e3181761fa3

522 35. Cedergren MI, Källén BAJ. Maternal obesity and infant heart defects. Obes Res. 2003;11: 1065–1071.
523 doi:10.1038/oby.2003.146

524 36. Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal Obesity and Risk for Birth Defects.
525 Pediatrics. 2003;111: 1152–1158.

526 37. Watkins ML, Botto LD. Maternal prepregnancy weight and congenital heart defects in offspring. Epidemiol Camb
527 Mass. 2001;12: 439–446.

528 38. Shaw GM, Todoroff K, Schaffer DM, Selvin S. Maternal height and prepregnancy body mass index as risk factors
529 for selected congenital anomalies. Paediatr Perinat Epidemiol. 2000;14: 234–239. doi:10.1046/j.1365-
530 3016.2000.00274.x

531 39. Liu X, Liu G, Wang P, Huang Y, Liu E, Li D, et al. Prevalence of congenital heart disease and its related risk
532 indicators among 90,796 Chinese infants aged less than 6 months in Tianjin. Int J Epidemiol. 2015;44: 884–893.
533 doi:10.1093/ije/dyv107

534 40. Agopian AJ, Moulik M, Gupta-Malhotra M, Marengo LK, Mitchell LE. Descriptive epidemiology of non-syndromic
535 complete atrioventricular canal defects. Paediatr Perinat Epidemiol. 2012;26: 515–524. doi:10.1111/ppe.12006

536 41. Vereczkey A, Gerencsér B, Czeizel AE, Szabó I. Association of certain chronic maternal diseases with the risk of
537 specific congenital heart defects: a population-based study. Eur J Obstet Gynecol Reprod Biol. 2014;182: 1–6.
538 doi:10.1016/j.ejogrb.2014.08.022

539 42. Kovalenko AA, Anda EE, Odland JØ, Nieboer E, Brenn T, Krettek A. Risk Factors for Ventricular Septal Defects in
540 Murmansk County, Russia: A Registry-Based Study. Int J Environ Res Public Health. 2018;15: 1320.
541 doi:10.3390/ijerph15071320

542 43. Vinceti M, Malagoli C, Rothman KJ, Rodolfi R, Astolfi G, Calzolari E, et al. Risk of birth defects associated with
543 maternal pregestational diabetes. Eur J Epidemiol. 2014;29: 411–418. doi:10.1007/s10654-014-9913-4

544 44. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, et al. Diabetes mellitus and birth defects. Am J
545 Obstet Gynecol. 2008;199: 237.e1–9. doi:10.1016/j.ajog.2008.06.028

546 45. Erickson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. Teratology.
547 1991;43: 41–51. doi:10.1002/tera.1420430106

548 46. Chou H-H, Chiou M-J, Liang F-W, Chen L-H, Lu T-H, Li C-Y. Association of maternal chronic disease with risk of
549 congenital heart disease in offspring. CMAJ Can Med Assoc J J Assoc Medicale Can. 2016;188: E438–E446.
550 doi:10.1503/cmaj.160061

551 47. Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986-
552 2000: a population-based cohort study. Birt Defects Res A Clin Mol Teratol. 2005;73: 605–611.
553 doi:10.1002/bdra.20172

554 48. Brodwall K, Leirgul E, Greve G, Vollset SE, Holmstrøm H, Tell GS, et al. Possible Common Aetiology behind
555 Maternal Preeclampsia and Congenital Heart Defects in the Child: a Cardiovascular Diseases in Norway Project
556 Study. Paediatr Perinat Epidemiol. 2016;30: 76–85. doi:10.1111/ppe.12252

557 49. Liu S, Rouleau J, León JA, Sauve R, Joseph KS, Ray JG. Impact of pre-pregnancy diabetes mellitus on congenital
558 anomalies, Canada, 2002-2012. Health Promot Chronic Dis Prev Can Res Policy Pract. 2015;35: 79–84.

559 50. Cai G, Sun X, Zhang L, Hong Q. Association between maternal body mass index and congenital heart defects in
560 offspring: a systematic review. Am J Obstet Gynecol. 2014;211: 91–117. doi:10.1016/j.ajog.2014.03.028

561 51. Zhu Y, Chen Y, Feng Y, Yu D, Mo X. Association between maternal body mass index and congenital heart defects
562 in infants: A meta-analysis. Congenit Heart Dis. 2018;13: 271–281. doi:10.1111/chd.12567

563 52. Zheng Z, Yang T, Chen L, Wang L, Zhang S, Wang T, et al. Increased maternal Body Mass Index is associated with
564 congenital heart defects: An updated meta-analysis of observational studies. Int J Cardiol. 2018;273: 112–120.
565 doi:10.1016/j.ijcard.2018.09.116

566 53. Simeone RM, Devine OJ, Marcinkevage JA, Gilboa SM, Razzaghi H, Bardenheier BH, et al. Diabetes and
567 congenital heart defects: a systematic review, meta-analysis, and modeling project. Am J Prev Med. 2015;48:
568 195–204. doi:10.1016/j.amepre.2014.09.002

569 54. Chen L, Yang T, Chen L, Wang L, Wang T, Zhao L, et al. Risk of congenital heart defects in offspring exposed to
570 maternal diabetes mellitus: an updated systematic review and meta-analysis. Arch Gynecol Obstet. 2019;300:
571 1491-1506. doi:10.1007/s00404-019-05376-6

572 55. Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of
573 Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. Pediatr Cardiol. 2015;36: 1442–
574 1451. doi:10.1007/s00246-015-1182-9

575 56. Parnell AS, Correa A, Reece EA. Pre-pregnancy Obesity as a Modifier of Gestational Diabetes and Birth Defects
576 Associations: A Systematic Review. Matern Child Health J. 2017;21: 1105–1120. doi:10.1007/s10995-016-2209-4

577 57. Denison FC, Aedla NR, Keag O, Hor K, Reynolds RM, Milne A, et al. Care of Women with Obesity in Pregnancy:
578 Green-top Guideline No. 72. BJOG Int J Obstet Gynaecol. 2019;126: e62–e106. doi:10.1111/1471-0528.15386

579 58. Helle E, Priest JR. Maternal Obesity and Diabetes Mellitus as Risk Factors for Congenital Heart Disease in the
580 Offspring. J Am Heart Assoc. 2020;9: e011541. doi:10.1161/JAHA.119.011541

581 59. Basu M, Zhu J-Y, LaHaye S, Majumdar U, Jiao K, Han Z, et al. Epigenetic mechanisms underlying maternal
582 diabetes-associated risk of congenital heart disease. JCI Insight. 2017;2: e95085. doi:10.1172/jci.insight.95085

583 60. Suzuki N, Svensson K, Eriksson UJ. High glucose concentration inhibits migration of rat cranial neural crest cells
584 in vitro. Diabetologia. 1996;39: 401–411. doi:10.1007/BF00400671

585 61. Wang X-Y, Li S, Wang G, Ma Z-L, Chuai M, Cao L, et al. High glucose environment inhibits cranial neural crest
586 survival by activating excessive autophagy in the chick embryo. Sci Rep. 2015;5: 18321. doi:10.1038/srep18321

587 62. Kumar SD, Vijaya M, Samy RP, Dheen ST, Ren M, Watt F, et al. Zinc supplementation prevents cardiomyocyte
588 apoptosis and congenital heart defects in embryos of diabetic mice. Free Radic Biol Med. 2012;53: 1595–1606.
589 doi:10.1016/j.freeradbiomed.2012.07.008

590 63. Wang F, Fisher SA, Zhong J, Wu Y, Yang P. Superoxide Dismutase 1 In Vivo Ameliorates Maternal Diabetes
591 Mellitus-Induced Apoptosis and Heart Defects Through Restoration of Impaired Wnt Signaling. Circ Cardiovasc
592 Genet. 2015;8: 665–676. doi:10.1161/CIRCGENETICS.115.001138

593 64. Engineer A, Saiyin T, Lu X, Kucey AS, Urquhart BL, Drysdale TA, et al. Sapropterin Treatment Prevents Congenital
594 Heart Defects Induced by Pregestational Diabetes Mellitus in Mice. J Am Heart Assoc. 2018;7: e009624.
595 doi:10.1161/JAHA.118.009624

596 65. Wang G, Huang W, Cui S, Li S, Wang X, Li Y, et al. Autophagy is involved in high glucose-induced heart tube
597 malformation. Cell Cycle Georget Tex. 2015;14: 772–783. doi:10.1080/15384101.2014.1000170

598 66. Reaven GM. Insulin resistance: from bit player to centre stage. CMAJ Can Med Assoc J J Assoc Medicale Can.
599 2011;183: 536–537. doi:10.1503/cmaj.101430

600 67. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet Lond Engl.
601 2016;387: 999–1011. doi:10.1016/S0140-6736(15)00070-7

602 68. WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Available from:
603 https://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/

604 69. National Institute for Health and Care Excellence. 2018 Surveillance of Diabetes in Pregnancy: Management
605 from Preconception to the Postnatal Period (NICE Guideline NG3). 2015. Available from:
606 https://www.nice.org.uk/guidance/ng3

607 70. von Versen-Hoeynck FM, Powers RW. Maternal-fetal metabolism in normal pregnancy and preeclampsia. Front
608 Biosci J Virtual Libr. 2007;12: 2457–2470. doi:10.2741/2247

609 71. Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in
610 prediction of small-for-gestational-age fetuses. Prenat Diagn. 2008;28: 1131–1135. doi:10.1002/pd.2141

611 72. Pihl K, Larsen T, Laursen I, Krebs L, Christiansen M. First trimester maternal serum pregnancy-specific beta-1-
612 glycoprotein (SP1) as a marker of adverse pregnancy outcome. Prenat Diagn. 2009;29: 1256–1261.
613 doi:10.1002/pd.2408

614 73. De Villiers CP, Hedley PL, Placing S, Wøjdemann KR, Shalmi A-C, Carlsen AL, et al. Placental protein-13 (PP13) in
615 combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and
616 early preeclampsia. Clin Chem Lab Med. 2017;56: 65–74. doi:10.1515/cclm-2017-0356

617 74. Thagaard IN, Krebs L, Holm J-C, Lange T, Larsen T, Christiansen M. Adiponectin and leptin as first trimester
618 markers for gestational diabetes mellitus: a cohort study. Clin Chem Lab Med. 2017;55: 1805–1812.
619 doi:10.1515/cclm-2017-0427

620 75. Hedley PL, Placing S, Wøjdemann K, Carlsen AL, Shalmi A-C, Sundberg K, et al. Free leptin index and PAPP-A: a
621 first trimester maternal serum screening test for pre-eclampsia. Prenat Diagn. 2010;30: 103–109.
622 doi:10.1002/pd.2337

623 76. Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutr. 2001;4: 611–624.
624 doi:10.1079/phn2001145

625 77. de Jong J, Garne E, Wender-Ozegowska E, Morgan M, de Jong-van den Berg LTW, Wang H. Insulin analogues in
626 pregnancy and specific congenital anomalies: a literature review. Diabetes Metab Res Rev. 2016;32: 366–375.
627 doi:10.1002/dmrr.2730

628 78. Given JE, Loane M, Garne E, Addor M-C, Bakker M, Bertaut-Nativel B, et al. Metformin exposure in first
629 trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ.
630 2018;361: k2477. doi:10.1136/bmj.k2477

631 79. Liu X, Ding G, Yang W, Feng X, Li Y, Liu H, et al. Maternal Body Mass Index and Risk of Congenital Heart Defects
632 in Infants: A Dose-Response Meta-Analysis. BioMed Res Int. 2019;2019: 1315796. doi:10.1155/2019/1315796

633 80. Berglind D, Willmer M, Näslund E, Tynelius P, Sørensen TIA, Rasmussen F. Differences in gestational weight gain
634 between pregnancies before and after maternal bariatric surgery correlate with differences in birth weight but
635 not with scores on the body mass index in early childhood. Pediatr Obes. 2014;9: 427–434. doi:10.1111/j.2047-
636 6310.2013.00205.x

637 81. Willmer M, Berglind D, Sørensen TIA, Näslund E, Tynelius P, Rasmussen F. Surgically induced interpregnancy
638 weight loss and prevalence of overweight and obesity in offspring. PloS One. 2013;8: e82247.
639 doi:10.1371/journal.pone.0082247

640 82. Best KE, Tennant PWG, Bell R, Rankin J. Impact of maternal body mass index on the antenatal detection of
641 congenital anomalies. BJOG Int J Obstet Gynaecol. 2012;119: 1503–1511. doi:10.1111/j.1471-
642 0528.2012.03462.x

643 83. Herskind AM, Almind Pedersen D, Christensen K. Increased prevalence of congenital heart defects in
644 monozygotic and dizygotic twins. Circulation. 2013;128: 1182–1188. doi:10.1161/CIRCULATIONAHA.113.002453

645 84. Pober BR. Williams-Beuren syndrome. N Engl J Med. 2010;362: 239–252. doi:10.1056/NEJMra0903074

646 85. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet EJHG. 2013;21: 8–13.
647 doi:10.1038/ejhg.2012.115

648 86. WHO. Obesity and overweight. 2020. Available from: https://www.who.int/news-room/fact-
649 sheets/detail/obesity-and-overweight

650 87. Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United
651 States, 2017–2018. 2020. Available from: https://www.cdc.gov/nchs/products/databriefs/db360.htm

652 88. Poston L, Caleyachetty R, Cnattingius S, Corvalán C, Uauy R, Herring S, et al. Preconceptional and maternal
653 obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016;4: 1025–1036.
654 doi:10.1016/S2213-8587(16)30217-0

655 89. Baumfeld Y, Novack L, Wiznitzer A, Sheiner E, Henkin Y, Sherf M, et al. Pre-Conception Dyslipidemia Is
656 Associated with Development of Preeclampsia and Gestational Diabetes Mellitus. PloS One. 2015;10: e0139164.
657 doi:10.1371/journal.pone.0139164

658 90. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in
659 later life: systematic review and meta-analysis. BMJ. 2007;335: 974. doi:10.1136/bmj.39335.385301.BE

660 91. Alonso-Ventura V, Li Y, Pasupuleti V, Roman YM, Hernandez AV, Pérez-López FR. Effects of preeclampsia and
661 eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis.
662 Metabolism. 2020;102: 154012. doi:10.1016/j.metabol.2019.154012

663

Supporting information

S1 Appendix. PRISMA checklist.

S1 Table. Search protocol. PubMed and Embase: Publications between January 1, 1990 and October 6, 2019.

S2 Table. Newcastle-Ottawa Quality Assessment Scale.

S3 Table. Characteristics of included studies. Studies listed after number of CHD cases: studies with most cases first etc. Abbreviations: ABDCCS, Atlanta Birth Defect Case-Control Study; BDRFSS, Birth Defects Risk Factor Surveillance Study; CHDs, congenital heart defects; CM, congenital malformations; CSL, The Consortium of Safe Labor; DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2; GDM, gestational diabetes mellitus; NBDPS, National Birth Defects Prevention Study; NOS, Newcastle Ottawa Scale; PE, preeclampsia; PGDM, pregestational diabetes.

S1 Fig. Maternal metabolic disorders and risk of heterotaxia in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S2 Fig. Maternal metabolic disorders and risk of univentricular heart in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; £, BMI ≥ 35 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio..

S3 Fig. Maternal metabolic disorders and risk of conotruncal defects in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1

or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S4 Fig. Maternal metabolic disorders and risk of common truncus in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S5 Fig. Maternal metabolic disorders and risk of transposition of the great arteries in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S6 Fig. Maternal metabolic disorders and risk of Tetralogy of Fallot in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio..

S7 Fig. Maternal metabolic disorders and risk of double outlet right ventricle in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted. Abbreviations: BMI, body mass

index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S8 Fig. Maternal metabolic disorders and risk of aortic arch defects in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; †, BMI 35-<40 kg/m^2. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S9 Fig. Maternal metabolic disorders and risk of atrioventricular septal defects in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S10 Fig. Maternal metabolic disorders and risk of total anomalous pulmonary venous return in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; Δ, estimates for anomalous pulmonary venous return; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

S11 Fig. Maternal metabolic disorders and risk of left ventricular outflow tract obstruction in the offspring. Obesity is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined from ICD-10 codes; £, BMI ≥ 35 kg/m^2. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

739 **S12 Fig. Maternal metabolic disorders and risk of hypoplastic left heart syndrome in the offspring.** Obesity is defined
740 as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are
741 defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £,
742 BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE.
743 Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,
744 odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

745 **S13 Fig. Maternal metabolic disorders and risk of coarctation of the aorta in the offspring.** Obesity is defined as BMI
746 ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as
747 DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35
748 kg/m^2; €, BMI > 29 kg/m^2; #, untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE.
749 Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,
750 odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

751 **S14 Fig. Maternal metabolic disorders and risk of aortic stenosis in the offspring.** Obesity is defined as BMI ≥ 30
752 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1
753 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; #,
754 untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM,
755 gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk
756 ratio.

757 **S15 Fig. Maternal metabolic disorders and risk of right ventricular outflow tract obstruction in the offspring.** Obesity
758 is defined as BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34;
759 PGDM are defined as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated
760 defects; £, BMI ≥ 35 kg/m^2; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1;
761 DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;
762 PR, prevalence ratio; RR, risk ratio.

763 **S16 Fig. Maternal metabolic disorders and risk of pulmonary valve stenosis in the offspring.** Obesity is defined as
764 BMI ≥ 30 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined

765 as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35
766 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension. Abbreviations: BMI, body mass index; DM1, diabetes type 1;
767 DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;
768 PR, prevalence ratio; RR, risk ratio.

769 **S17 Fig. Maternal metabolic disorders and risk of Ebstein's anomaly in the offspring.** Obesity is defined as BMI ≥ 30
770 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1
771 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2; #,
772 untreated hypertension; $, Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index;
773 DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM,
774 pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

775 **S18 Fig. Maternal metabolic disorders and risk of septal defects in the offspring.** Obesity is defined as BMI ≥ 30
776 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1
777 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; £, BMI ≥ 35 kg/m^2.
778 Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,
779 odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

780 **S19 Fig. Maternal metabolic disorders and risk of ventricular septal defects in the offspring.** Obesity is defined as
781 BMI ≥ 30 kg/m2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined
782 as DM1 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity
783 defined from ICD-10 codes; £, BMI ≥ 35 kg/m2; €, BMI > 29 kg/m2; †, BMI 35-<40 kg/m2; #, untreated hypertension; $,
784 Brodwall et al. pooled early-onset PE and severe PE. Abbreviations: BMI, body mass index; DM1, diabetes type 1;
785 DM2, diabetes type 2; GDM, gestational diabetes; OR, odds ratio; PE, preeclampsia; PGDM, pregestational diabetes;
786 PR, prevalence ratio; RR, risk ratio.

787 **S20 Fig. Maternal metabolic disorders and risk of atrial septal defects in the offspring.** Obesity is defined as BMI ≥ 30
788 kg/m^2 unless other is stated; early-onset PE defined as debut before gestational week 34; PGDM are defined as DM1
789 or DM2; all risk estimates are adjusted unless other is stated; *, not adjusted; §, isolated defects; ¤, obesity defined
790 from ICD-10 codes; £, BMI ≥ 35 kg/m^2; €, BMI > 29 kg/m^2; †, BMI 35-<40 kg/m^2; #, untreated hypertension.

791 Abbreviations: BMI, body mass index; DM1, diabetes type 1; DM2, diabetes type 2; GDM, gestational diabetes; OR,
792 odds ratio; PE, preeclampsia; PGDM, pregestational diabetes; PR, prevalence ratio; RR, risk ratio.

793

794


Records identified from database search (PubMed and Embase) (n = 2 053)
Additional records identified from other sources (e.g., reference lists) (n = 23)
Records screened (titles and abstracts) (n = 2 076)
1 990 records excluded
Full-text articles assessed for eligibility (n = 86)
50 full-text articles excluded, with reasons:
The studies were not related to our topic (n = 9)
The studies did not report specific CHDs referable to ICD-10 codes (n = 22)
The studies had less than 15 CHD cases available for comparison (n = 9)
Studies without healthy controls or a non-exposed control group (n = 9)
Studies incl. data presented elsewhere (n = 1)
Full-text articles evaluated with NOS scores (n = 36)
6 articles excluded due to low methodological quality, NOS < 7
Studies included in review (n = 30)
Case-control studies (n = 13)
Cohort studies (n = 17)

Any congenital heart defect	Study		
Obesity	Brite et al. [15]	OR	1.26
	Gilboa et al. [31] §£	OR	1.31
	Liu et al. [19] ¤	OR	1.48
	Liu et al. [39] ¥	OR	1.16
	Mills et al. [32]	OR	1.15
	Watkins et al. [37] §€	OR	1.29
	Persson et al. [14] †	PR	1.37
PGDM	Correa et al. [44] §	OR	4.64
	Leirgul et al. [18]	RR	2.92
	Øyen et al. [16]	RR	3.96
	Hoang et al. [17]	PR	3.24
DM1	Chou et al. [46]	OR	2.32
	Liu et al. [19]	OR	4.65
	Ludvigsson et al. [13]	RR	3.19
DM2	Chou et al. [46]	OR	2.85
	Liu et al. [19]	OR	4.12
GDM	Correa et al. [44] §	OR	1.59
	Liu et al. [39]	OR	1.80
	Leirgul et al. [18]	RR	1.47
	Hoang et al. [17]	PR	1.49
Hypertension	Liu et al. [19]	OR	1.81
	Chou et al. [46]	OR	1.87
	Fisher et al. [20] #	OR	1.23
PE (early-onset)	Boyd et al. [21]	OR	7.00
	Brodwall et al. [48] ‡	RR	2.80
	Auger et al. [22] @	PR	5.53
Obesity+GDM	Gilboa et al. [31]	OR	1.82